Björner Sofie, Rosendahl Ann H, Tryggvadottir Helga, Simonsson Maria, Jirström Karin, Borgquist Signe, Rose Carsten, Ingvar Christian, Jernström Helena
Skåne University Hospital, Department of Clinical Sciences Lund, Oncology and Pathology, Faculty of Medicine, Lund University, Lund, Sweden.
CREATE Health, Department of Immunotechnology, Lund University, Medicon Village, Lund, Sweden.
Front Endocrinol (Lausanne). 2018 Jun 6;9:306. doi: 10.3389/fendo.2018.00306. eCollection 2018.
Coffee is associated with decreased breast cancer risk, but the impact of body mass index (BMI) in combination with coffee consumption on prognosis is unclear. The suppressive effect of coffee constituents on the insulin-like growth factor receptor 1 (IGF1R) levels in breast cancer cells may play a role. The aim was to investigate the prognostic impact of coffee consumption and possible associations with tumor-specific IGF1R protein expression and BMI in a population-based cohort in Sweden, comprising 1,014 primary breast cancer patients without pretreatment enrolled 2002-2012 and followed for up to 13 years. Patients with higher coffee consumption had lower tumor IGF1R levels ( = 0.025), but only among the normal-weight patients ( = 0.005). Coffee did not impact the recurrence-risk overall. However, tamoxifen-treated patients with ER tumors drinking ≥ 2 cups of coffee/day had lower recurrence-risk [adjusted HR (HR) 0.57, 95% CI, 0.34-0.97] compared with patients with lower intake, although only among normal-weight patients (HR 0.37, 95% CI: 0.17-0.78; = 0.039). Similarly, coffee consumption ≥ 2 cups/day was associated with significantly lower recurrence-risk among the 640 radiotherapy-treated patients irrespective of BMI (HR 0.59, 95% CI 0.36-0.98) and in the 296 normal-weight patients (HR 0.36, 95% CI 0.17-0.76) but not in the 329 overweight or obese patients (HR 0.88, 95% CI 0.42-1.82) although the interaction was not significant ( = 0.093). In conclusion, coffee consumption was negatively associated with tumor-specific IGF1R levels only among normal-weight patients. Though, IGF1R did not explain the association between coffee intake and improved prognosis among normal-weight tamoxifen- or radiotherapy-treated patients. Studies of IGF1R-targeting therapies may benefit from taking BMI and coffee consumption into account.
咖啡与降低乳腺癌风险相关，但体重指数（BMI）与咖啡摄入量相结合对预后的影响尚不清楚。咖啡成分对乳腺癌细胞中胰岛素样生长因子受体1（IGF1R）水平的抑制作用可能起到一定作用。目的是在瑞典一个基于人群的队列中，调查咖啡摄入量的预后影响以及与肿瘤特异性IGF1R蛋白表达和BMI的可能关联，该队列包括2002年至2012年入组的1014例未经预处理的原发性乳腺癌患者，随访长达13年。咖啡摄入量较高的患者肿瘤IGF1R水平较低（P = 0.025），但仅在体重正常的患者中如此（P = 0.005）。咖啡总体上并未影响复发风险。然而，与摄入量较低的患者相比，每天饮用≥2杯咖啡的他莫昔芬治疗的ER肿瘤患者复发风险较低[调整后风险比（HR）0.57，95%置信区间（CI），0.34 - 0.97]，不过仅在体重正常的患者中如此（HR 0.37，95% CI：0.17 - 0.78；P = 0.039）。同样，无论BMI如何，在640例接受放疗的患者中，每天饮用≥2杯咖啡与显著较低的复发风险相关（HR 0.59，95% CI 0.36 - 0.98），在296例体重正常的患者中也是如此（HR 0.36，95% CI 0.17 - 0.76），但在329例超重或肥胖患者中并非如此（HR 0.88，95% CI 0.42 - 1.82），尽管交互作用不显著（P = 0.093）。总之，仅在体重正常的患者中，咖啡摄入量与肿瘤特异性IGF1R水平呈负相关。不过，IGF1R并不能解释体重正常的接受他莫昔芬治疗或放疗的患者中咖啡摄入量与预后改善之间的关联。针对IGF1R的治疗研究可能需要考虑BMI和咖啡摄入量。
